Conclusions
Immunotherapy outcomes in small studies have shown good data for increasing survival rates at all yearly intervals in MM of the head and neck. Larger clinical trials should be done to accurately distinguish efficacy and survival outcomes of immunotherapy when compared to treatment modalities excluding immunotherapy. The ability to perform larger trials are, however, limited by the rarity of MM of the head and neck.